C Ardiet

849 total citations
39 papers, 694 citations indexed

About

C Ardiet is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, C Ardiet has authored 39 papers receiving a total of 694 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 16 papers in Molecular Biology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in C Ardiet's work include Cancer therapeutics and mechanisms (11 papers), Cancer Treatment and Pharmacology (10 papers) and Safe Handling of Antineoplastic Drugs (5 papers). C Ardiet is often cited by papers focused on Cancer therapeutics and mechanisms (11 papers), Cancer Treatment and Pharmacology (10 papers) and Safe Handling of Antineoplastic Drugs (5 papers). C Ardiet collaborates with scholars based in France, United States and Belgium. C Ardiet's co-authors include Brigitte Tranchand, Thierry Philip, Paul Rebattu, Pierre Biron, Bertrand Favier, Jean‐Paul Guastalla, G. Catimel, A Dumortier, Gilles Freyer and Franck Chauvin and has published in prestigious journals such as Annals of Oncology, International Journal of Cancer and Biochemical Pharmacology.

In The Last Decade

C Ardiet

39 papers receiving 673 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C Ardiet France 16 324 240 96 87 79 39 694
Bertrand Pourroy France 17 294 0.9× 331 1.4× 49 0.5× 78 0.9× 64 0.8× 47 823
Mirjam Crul Netherlands 18 447 1.4× 490 2.0× 65 0.7× 187 2.1× 127 1.6× 75 1.2k
John A. Benvenuto United States 14 279 0.9× 226 0.9× 20 0.2× 76 0.9× 46 0.6× 33 589
Florent Puisset France 13 215 0.7× 106 0.4× 48 0.5× 113 1.3× 58 0.7× 35 521
Sachin Shah United States 13 286 0.9× 211 0.9× 103 1.1× 172 2.0× 52 0.7× 25 737
Jan Ouwerkerk Netherlands 11 250 0.8× 153 0.6× 86 0.9× 109 1.3× 27 0.3× 17 506
Mark J. Ratain United States 12 351 1.1× 153 0.6× 22 0.2× 89 1.0× 44 0.6× 21 602
Beverly Meadows United States 11 382 1.2× 164 0.7× 14 0.1× 37 0.4× 170 2.2× 13 610
E. Boven Netherlands 11 503 1.6× 308 1.3× 40 0.4× 116 1.3× 46 0.6× 25 770
Jeroen J. M. A. Hendrikx Netherlands 17 527 1.6× 221 0.9× 36 0.4× 193 2.2× 97 1.2× 57 939

Countries citing papers authored by C Ardiet

Since Specialization
Citations

This map shows the geographic impact of C Ardiet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C Ardiet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C Ardiet more than expected).

Fields of papers citing papers by C Ardiet

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C Ardiet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C Ardiet. The network helps show where C Ardiet may publish in the future.

Co-authorship network of co-authors of C Ardiet

This figure shows the co-authorship network connecting the top 25 collaborators of C Ardiet. A scholar is included among the top collaborators of C Ardiet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C Ardiet. C Ardiet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Favier, Bertrand, et al.. (2008). Évaluation de la contamination des gants et des mains du personnel infirmier avant et après formation à la manipulation des anticancéreux. 63(1). 20–24. 1 indexed citations
2.
Forest, Valérie, Michel Péoc’h, C Ardiet, et al.. (2005). In vivo cryochemotherapy of a human lung cancer model. Cryobiology. 51(1). 92–101. 20 indexed citations
3.
Dumontet, Charles, J. Jaubert, Catherine Sebban, et al.. (2003). Clinical and pharmacokinetic phase II study of fotemustine in refractory and relapsing multiple myeloma patients. Annals of Oncology. 14(4). 615–622. 7 indexed citations
4.
Favier, Bertrand, F. Rull, C. Pivot, et al.. (2001). Surface and human contamination with 5-fluorouracil in six hospital pharmacies. Journal de Pharmacie Clinique. 20(3). 6 indexed citations
5.
Favier, Bertrand, et al.. (2001). Evaluation de la contamination de l'environnement matériel et humain par le 5-fluoro-uracile lors de la manipulation en unités de reconstitution des chimiothérapies. Journal de Pharmacie Clinique. 20(3). 157–162. 6 indexed citations
6.
7.
8.
Bachelot, Thomas, Isabelle Ray‐Coquard, G. Catimel, et al.. (2000). Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials. Annals of Oncology. 11(2). 151–156. 98 indexed citations
9.
Freyer, Gilles, Brigitte Tranchand, Blandine Ligneau, et al.. (2000). Population pharmacokinetics of doxorubicin, etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre study. British Journal of Clinical Pharmacology. 50(4). 315–324. 35 indexed citations
10.
Tranchand, Brigitte, Étienne Chatelut, Gilles Freyer, et al.. (1999). A limited-sampling strategy for estimation of etoposide pharmacokinetics in cancer patients. Cancer Chemotherapy and Pharmacology. 43(4). 316–322. 32 indexed citations
11.
Tranchand, Brigitte, G. Catimel, Catherine Lucas, et al.. (1998). Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 41(4). 281–291. 23 indexed citations
12.
Freyer, Gilles, et al.. (1997). Pharmacokinetic studies in cancer chemotherapy: Usefulness in clinical practice. Cancer Treatment Reviews. 23(3). 153–169. 22 indexed citations
13.
Dirix, Luc, G. Catimel, René Verdonk, et al.. (1995). Phase I and pharmacokinetic study of KW-2149 given by 24 hours continuous infusion. Investigational New Drugs. 13(2). 133–136. 2 indexed citations
14.
Tranchand, Brigitte, Catherine Lucas, Pierre Biron, et al.. (1993). Phase I pharmacokinetics study of high-dose fotemustine and its metabolite 2-chloroethanol in patients with high-grade gliomas. Cancer Chemotherapy and Pharmacology. 32(1). 46–52. 6 indexed citations
15.
Dimanche‐Boitrel, Marie‐Thérèse, Philippe Genne, Christian Le Grimellec, et al.. (1992). Confluence‐dependent resistance in human colon cancer cells: Role of reduced drug accumulation and low intrinsic chemosensitivity of resting cells. International Journal of Cancer. 50(5). 677–682. 75 indexed citations
16.
Ings, R. M. J., Eric Lelièvre, C Ardiet, et al.. (1992). Value of early pharmacodynamic and pharmacokinetic investigations with anticancer drugs: data from phase I tolerance studies on a new vinca alkaloid derivative. Xenobiotica. 22(7). 871–880. 4 indexed citations
17.
Ploin, Dominique, Brigitte Tranchand, Jean‐Paul Guastalla, et al.. (1992). Pharmacokinetically guided dosing for intravenous melphalan: a pilot study in patients with advanced ovarian adenocarcinoma. European Journal of Cancer. 28(8-9). 1311–1315. 18 indexed citations
18.
Iliadis, Athanassios, et al.. (1990). Bayesian Estimation of Cyclosporine Clearance in Bone Marrow Graft. Therapeutic Drug Monitoring. 12(1). 16–22. 13 indexed citations
19.
Tranchand, Brigitte, et al.. (1989). High-dose melphalan dosage adjustment: possibility of using a test-dose. Cancer Chemotherapy and Pharmacology. 23(2). 95–100. 31 indexed citations
20.
Pinkerton, CR, B. J. McDermott, Thierry Philip, et al.. (1988). Continuous vincristine infusion as part of a high dose chemoradiotherapy regimen: drug kinetics and toxicity. Cancer Chemotherapy and Pharmacology. 22(3). 271–274. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bertrand Pourroy Breakdown of academic impact, for papers by Mirjam Crul Breakdown of academic impact, for papers by John A. Benvenuto Breakdown of academic impact, for papers by Florent Puisset Breakdown of academic impact, for papers by Sachin Shah Breakdown of academic impact, for papers by Jan Ouwerkerk Breakdown of academic impact, for papers by Mark J. Ratain Breakdown of academic impact, for papers by Beverly Meadows Breakdown of academic impact, for papers by E. Boven Breakdown of academic impact, for papers by Jeroen J. M. A. Hendrikx
Rankless by CCL
2026